MedTrace Logo

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

NCT04161352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-11-13

No results posted yet for this study

Summary

The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.

Conditions

  • Unresectable Stage III NSCLC

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-25
Primary Completion
2022-06-30
Completion
2023-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161352 on ClinicalTrials.gov